PAR News: Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of dis - 11th Apr 2023, 7:00pm

annb0t

Top 20
Paradigm Biopharmaceuticals

Top-line phase 2 trial data shows disease modifying potential and pain reduction

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:pAR) says analysis of six-month trial data shows injectable pentosan polysulfate sodium (iPPS) may slow the progression of osteoarthritis of the knee.

In October 2022, Paradigm said its phase 2 clinical study met its primary endpoint of a change from baseline to day 56 in one ...

>>> Read more: Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
 
Top Bottom